The estimated Net Worth of John A Roberts is at least $1.34 Milion dollars as of 31 January 2019. Mr. Roberts owns over 185,436 units of Cancer Genetics stock worth over $1,342,338 and over the last 8 years he sold CGIX stock worth over $0. In addition, he makes $0 as President, Chief Executive Officer a Principal Financial Officer and Principal Accounting Officer at Cancer Genetics.
John has made over 3 trades of the Cancer Genetics stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 185,436 units of CGIX stock worth $42,650 on 31 January 2019.
The largest trade he's ever made was buying 185,436 units of Cancer Genetics stock on 31 January 2019 worth over $42,650. On average, John trades about 49,606 units every 69 days since 2016. As of 31 January 2019 he still owns at least 297,636 units of Cancer Genetics stock.
You can see the complete history of Mr. Roberts stock trades at the bottom of the page.
John A. Roberts serves as President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer of the Company. He had been serving as the Company’s Chief Executive Officer on an interim basis since February 2, 2018 in addition to his role as our Chief Operating Officer and Executive Vice President, Finance, a position he has held since he joined the Company in July 2016. Prior to joining Cancer Genetics, from August 1, 2015 to June 30, 2016, Mr. Roberts served as the Chief Financial Officer for VirMedica, Inc., an innovative technology solutions company that provides an end-to-end platform that enables specialty drug manufacturers and pharmacies to optimize product commercialization and management. Prior to VirMedica, from August 1, 2011 to July 31, 2015, Mr. Roberts was the Chief Financial and Administrative Officer for AdvantEdge Healthcare Solutions, a global healthcare analytics and services organization. Prior to that, Mr. Roberts was the Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded healthcare-centric mobile software and solutions provider. He has also held CFO roles at leading public medical device and healthcare services firms including Clarient, Inc., a publicly-traded provider of diagnostic laboratory services and Daou Systems, Inc., a publicly-traded healthcare IT software development and services firm. In addition, he has held key senior executive roles with MEDecision, Inc., HealthOnline, Inc. and the Center for Health Information. Mr. Roberts earned a Bachelor of Science and a Master’s degree in Business Administration from the University of Maine. He is Chairman of the Board of Directors for the Drug Information Association (DIA), a global neutral forum enabling drug developers and regulators access to insights and collaboration.
John Roberts is 59, he's been the President, Chief Executive Officer a Principal Financial Officer and Principal Accounting Officer of Cancer Genetics since 2020. There are 4 older and 3 younger executives at Cancer Genetics. The oldest executive at Cancer Genetics Inc. is John Pappajohn, 90, who is the Non-Executive Chairman of the Board.
John's mailing address filed with the SEC is 201 NJ-17, Rutherford, NJ 07070, USA.
Over the last 12 years, insiders at Cancer Genetics have traded over $1,720,897 worth of Cancer Genetics stock and bought 3,891,559 units worth $4,573,241 . The most active insiders traders include John Pappajohn, Tommy G Thompson a John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of $340,207. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth $42,650.
Cancer Genetics executives and other stock owners filed with the SEC include: